Early clinical trials, in which over 1000 cancer patients received dendritic cell (DC) vaccines,
tested different vaccine preparations, but they did not always induce sufficient acquired …

Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective
antitumor immune response against tumor antigens and was first explored in a clinical trial …

Dendritic cells (DCs) have shown great potential as a component or target in the landscape
of cancer immunotherapy. Different in vivo and ex vivo strategies of DC vaccine generation …

During the last decade use of dendritic cells (DC) has moved from murine and in vitro
studies to clinical trials as adjuvant in cancer immunotherapy. Here they function as delivery …

Dendritic cells (DC) are recognized as the most potent antigen-presenting cells with the
ability to stimulate naive resting T cells and to initiate primary immune responses …

The ability of immune therapies to control cancer has recently generated intense interest.
This therapeutic outcome is reliant on T cell recognition of tumour cells. The natural function …

The development of immunotherapeutic methods for the treatment of oncological diseases
have made it possible to improve the effectiveness of standard therapies. There was no …

Dendritic cells (DC) have been tested in cancer immunotherapy clinical trials for two
decades. Over this time, the methods of DC culture (or manufacture) have evolved, the …

Dendritic cells (DCs) are the most potent professional antigen-presenting cells, capable of
initiating proper adaptive immune responses. Although tumor-infiltrating DCs are able to …

Dendritic cells (DCs) can initiate and direct adaptive immune responses. This ability is
exploitable in DC vaccination strategies, in which DCs are educated ex vivo to present tumor …